Paclitaxel/Carboplatin
Phase 3Small molecule
Paclitaxel/Carboplatin is one of 110 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 3.
3
Indications
10
Total Trials
3
Active Trials
109
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Paclitaxel/Carboplatin
CCTI BioPharma
Phase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Vizimpro
PfizerPreclinical
Remeron
OOrganon and Co
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Preclinical
Immune Checkpoint Inhibitors
PPeking Union Medical College Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Carboplatin2 trials
Non-Small Cell Lung Cancer1 trial
Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer
Completed·—·Phase 2·NCT01196234·84 enrolled
Endometrial Carcinoma1 trial
Locally Advanced1 trial
4 more indications
Locally Advanced Head and Neck Cancer1 trial
Triple-Negative Breast Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Paclitaxel/Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCTI BioPharma